Forestar Group was upgraded to buy at TheStreet Ratings.
Northeast Bancorp was downgraded to hold at TheStreet Ratings.
Intel earnings estimates were reduced at UBS. The lowered outlook reflects a sub-seasonal PC client trend, said UBS. Price target remains $22.50.
Onyx Pharmaceuticals price target was increased to $105 by JPMorgan. Palbociclib (palbo, or PD-991), a breast cancer drug, is now included in the valuation, said JPMorgan.
Verisign price target was increased to $50 at Citigroup. The new price target reflects the likelihood of a significant debt raise, said Citigroup.
Zillow price target increased at Citi. The initial mid-term outlook provided at Z's fist analyst day led to a new price target of $70, said Citigroup.
Red Hat estimates and price target cut at MKM. RHT earnings estimates through 2014 were reduced on management guidance, said MKM Partners. The new price target is $53.
Progress Software price target was reduced to $29 at Benchmark. Lower fiscal 2Q guidance reflects uncertainty related to its ongoing business transformation, said Benchmark.
Verint Systems estimates and price target increased at JPMorgan. VRNT fourth quarter earnings were better than expected and outlook was solid, said JPMorgan. Earnings estimates were increased and the price target was bumped to $41.
Five Below estimates reduced at UBS on weaker than expected guidance from management. The new outlook includes investments for growth, said UBS. Price target remains $35.
Ryder Systems estimates and price target were increased at KeyBanc to reflect a favorable lease pipeline. Price target goes to $68.
Bed Bath & Beyond estimates reduced at Oppenheimer ahead of the earnings release. Sales and margin weakness have likely persisted, said Oppenheimer
>To submit a news tip, email: firstname.lastname@example.org.